IDEAYA Biosciences, Inc.

IDYA · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders2.2%

Institutions108.4%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$218.71M	$7.00M	$50.93M	$27.94M	$19.54M	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$159.31M	-$326.98M	-$62.50M	-$50.27M	-$35.34M	-$44.27M
Operating income as a percentage of revenue.	-72.8%	-4671.1%	-122.7%	-179.9%	-180.9%	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$113.70M	-$274.48M	-$58.66M	-$49.76M	-$34.49M	-$41.98M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.28	$-3.36	$-1.42	$-1.41	$-1.40	$-3.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.28	$-3.36	$-1.42	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$112.83M	$84.38M	$68.63M	$92.05M	$72.04M	$34.07M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.11B	$1.12B	$387.97M	$381.35M	$298.27M	$113.00M
Everything the company owes — debt, unpaid bills, and other obligations.	$86.39M	$64.94M	$38.51M	$79.83M	$100.00M	$12.60M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$1.02B	$1.06B	$349.45M	$301.51M	$198.27M	$100.40M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$71.10M	-$247.58M	-$87.17M	-$55.78M	$55.46M	-$39.31M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$2.37M	$3.86M	$3.44M	$2.64M	$493000	$1.35M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$73.47M	-$251.44M	-$90.62M	-$58.42M	$54.97M	-$40.67M

	You	Peer avg
Revenue Growth	–	+23.1%
ROE	-16.2%	-43.5%

IDEAYA Biosciences, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison